GlassScriptPhysician profile
Brett Allen Forehand
NPI 1427430180
$3,601.41
in general payments reported to CMS, 2019-2025
46 companies · $892 in 2025
The $892 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $838 · 2022: $350 · 2023: $1,097 · 2024: $424 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,348 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.97 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $359.36 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $269.70 | 2021-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $260.95 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $250.01 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Abbvie INC. | $248.70 | 2021-2024 | |
| Pfizer INC. | $205.33 | 2021-2024 | |
| Glaxosmithkline, LLC. | $151.50 | 2023-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Dexcom, INC. | $123.48 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $116.55 | 2022-2025 | |
| Harmony Biosciences LLC | $114.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.98 | 2021-2025 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.23 | 2021-2023 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $90.55 | 2021 | |
| Esperion Therapeutics, INC. | $86.77 | 2021-2022 | |
| Verona Pharma, INC. | $80.57 | 2025 | Ohtuvayre |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $78.78 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $74.79 | 2025 | |
| Astellas Pharma US INC | $74.46 | 2021-2024 | Veozah |
| Abbott Laboratories | $74.10 | 2021-2024 | Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $64.38 | 2022 | |
| United Therapeutics Corporation | $52.18 | 2025 | Tyvaso |
| Viatris Specialty LLC | $40.94 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $38.75 | 2023-2025 | Verquvo, Steglatro, Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $36.71 | 2023 | Trintellix |
| Exact Sciences Corporation | $35.96 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $35.69 | 2023 | Austedo Xr, Ajovy |
| Grifols USA, LLC | $34.09 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $33.57 | 2025 | Dupixent |
| Amarin Pharma, INC. | $32.67 | 2021 | |
| Seqirus USA INC | $27.76 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.39 | 2025 | |
| Shield Therapeutics INC | $24.85 | 2024 | |
| Bausch Health US, LLC | $22.37 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.23 | 2025 | Opsumit |
| Eisai INC. | $20.31 | 2021 | |
| Vifor Pharma, INC. | $20.17 | 2023 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $18.54 | 2023 | Eliquis |
| Jazz Pharmaceuticals INC. | $16.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.79 | 2023 | Quviviq |
| Ani Pharmaceuticals, INC. | $15.51 | 2025 | Purified Cortrophin Gel |
| Linus Health, INC. | $15.45 | 2023 | |
| Electromed, INC. | $15.40 | 2025 | Smartvest |
| Medtronic, INC. | $14.56 | 2024 | Kyphon Express II Kyphopak Tray |
| Endo Pharmaceuticals INC. | $14.47 | 2021 | |
| Inspire Medical Systems, INC. | $14.20 | 2025 | Inspire |
| Phadia US INC. | $13.99 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Forehand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.